Protocol Ledger

NCT06932068 · Phase II · RECRUITING

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Interventional Phase II clinical trial protocol NCT06932068 sponsored by Qilu Hospital of Shandong University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-26 Enrollment: 77 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06932068
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)77 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06932068
Protocol FieldVerified Registry Value
NCT IdentifierNCT06932068
Consolidated Lead SponsorQilu Hospital of Shandong University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment77 participants (ESTIMATED)
Registered Start Date2025-03-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06932068
Hospital Research SiteLocationSite Profile
The first affiliated hospital of Zhengzhou UniversityZhengzhou, ChinaOpen Hospital Dossier ->
Qilu Hospital of Shandong UniversityJinan, ChinaOpen Hospital Dossier ->
Jinan Central HospitalJinan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI